Supervalu offers pre-diabetes blood glucose screenings
FRANKLIN PARK, Ill. Recognizing that the chances of developing diabetes can be significantly lessened if the warning signs are discovered early, Supervalu is offering this holiday season the opportunity for customers to engage in a pre-diabetes glucose screening program.
Considering the dietary habits that many Americans adopt during the holiday season, a large percentage of pre-diabetics may be doing significant damage to their health without even realizing it. “As the holiday season approaches, we encourage potentially at-risk adults to get the information they need to make wise and healthy choices before they notice symptoms,” said registered pharmacist Nancy Lyons, a certified diabetes educator and manager of Supervalu’s Diabetes Care Program. “In many cases, diabetes can be delayed or even prevented with early detection and by making appropriate changes in diet and physical activity.”
The screening test, which can be made by appointment at many of Supervalu-associated pharmacies, measures blood glucose levels simply by taking a few drops of blood from a patient’s finger. Adults are considered pre-diabetic if their blood glucose levels are higher than normal and below the threshold for a diagnosis of diabetes. Pre-diabetes affects an estimated 54 million Americans and, if not treated, can lead to the onset of Type-2 diabetes.
Lifestyle changes, such as healthy diet and exercise can delay and even prevent Type-2 diabetes. “Supervalu understands that good health starts with good nutrition and preventative measures like those provided by our Diabetes Care Program,” said Bill Baker, registered pharmacist and manager of Clinical Programs Marketing.
In addition to elevated blood glucose levels, other risk signs are high blood pressure, obesity, low HDL cholesterol, and a family history of diabetes. “By offering health screenings and quality education at our in-store pharmacies, we believe we can help customers manage their health and have a better quality of life,” added Baker.
Screenings are available throughout the year at nearly 500 locations, including Jewel-Osco, Albertsons, Shaw’s Osco and Sav-on Pharmacy. Patients can schedule an appointment and find the most convenient location by calling 800-783-0458.
Celgene to acquire Pharmion for $72/share
SUMMIT, N.J. Celgene and Pharmion have announced a merger agreement, under which Celgene has agreed to acquire Pharmion. Celgene will acquire all of Pharmion’s outstanding shares of common stock for $72 per share payable in cash and share of Celgene common stock.
Under the agreement, Celgene will acquire the rights to three popular Pharmion oncology drugs: Revlimid, Thalomid, and Vidaza. Thalmoid and Revlimid are used to treat patients with multiple myeloma. Vidaza is used to treat myelodysplastic syndromes.
“The acquisition of Pharmion is an exceptional strategic fit that will expand our role as a leader in hematology and oncology,” said Sol Barer, chairman and chief executive officer of Celgene Corporation. “Our combined global infrastructure will leverage the therapeutic and commercial potential of Pharmion’s products, particularly Vidaza, which has the potential to become a major global therapy. By bringing together the talents and resources of both companies, we move closer to our vision of becoming a leading hematology and oncology company in the world, expanding our industry leading programs for safety, access and patient support.”
RxHub introduces Rx 4 Success e-prescribing program
ST. PAUL, Minn. RxHub, a company that keeps track of patient-specific medication history and pharmacy benefit information, has announced a new product for e-prescribing, the Rx 4 Success.
The new program was developed to target four main areas of e-prescribing: utilization of Centers for Medicaid and Medicare Services approved ePrescribing transactions including eligibility, formulary and benefits, and medication history. The program will also integrate true electronic delivery of prescriptions to retail and mail order pharmacies. It will also keep consistent rules-based applications of clinical decision support content and formulate transactional data to support the development of outcomes based on pay-for-performance programs.
“We are extremely proud to be associated with our growing roster of partners which includes many of the healthcare industry’s foremost technology innovators,” stated Doug Johnson, vice president of business development for technology partners at RxHub. “Their collective vision not only helped shape Rx 4 Success but provides the foundation for ongoing market driven performance analysis and improvement.”
Rx 4 Success will become a participation requirement for technology partners connected to the RxHub network as of July 31, 2008.